These criteria include: (1) the study design being an RCT or cohort study, (2) the subjects having a clinical diagnosis of NAFLD/NASH, (3) the intervention drug being either an SGLT2 inhibitor or pioglitazone, and (4) the study reporting results for changes in liver steatosis, liver enzyme, and liver fibrosis of the SGLT2 group or pioglitazone group in comparison to the control group. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.